Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8BrF17 |
Molecular Weight | 498.962 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
InChI
InChIKey=WTWWXOGTJWMJHI-UHFFFAOYSA-N
InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
Molecular Formula | C8BrF17 |
Molecular Weight | 498.962 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191624/
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191624/
Perflubron is a contrast agent used for signal enhancement during the indicated ultrasound imaging procedures. Perflubron is a constituent of blood substitute, indicated for liquid breathing.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.16 mg/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11171732 |
14 mL/kg single, respiratory dose: 14 mL/kg route of administration: Respiratory experiment type: SINGLE co-administered: |
PERFLUBRON serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
High-frequency oscillatory ventilation of the perfluorocarbon-filled lung: dose-response relationships in an animal model of acute lung injury. | 2001 Apr |
|
Intratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs. | 2001 Aug |
|
Selective tracheal gas insufflation during partial liquid ventilation improves lung function in an animal model of unilateral acute lung injury. | 2001 Dec |
|
Pulmonary arterial morphometry from microfocal X-ray computed tomography. | 2001 Dec |
|
Perflubron emulsion reduces inflammation during extracorporeal circulation. | 2001 Jul |
|
Optimizing intrapulmonary perfluorocarbon distribution: fluoroscopic comparison of mode of ventilation and body position. | 2001 Mar |
|
Seventy-two hours hypothermic intestinal preservation study using a new perfluorocarbon emulsion. | 2001 May |
|
Exposure to perflubron is associated with decreased Syk phosphorylation in human neutrophils. | 2001 Nov |
|
Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature. | 2001 Nov 15 |
|
Using liquid ventilation to treat patients with acute respiratory distress syndrome: a guide to a breath of fresh liquid. | 2001 Oct |
|
Partial liquid ventilation with low dose of perflubron and a low stretch ventilation strategy improves oxygenation in a rabbit model of surfactant depletion. | 2002 |
|
Comparison of effects of perflubron and surfactant lung lavage on pulmonary gas exchange in a piglet model of meconium aspiration. | 2002 |
|
Oxygen carriers. | 2002 Aug |
|
A second-generation blood substitute (perflubron emulsion) increases the blood solubility of modern volatile anesthetics in vitro. | 2002 Aug |
|
Combined bactericidal activity of perfluorooctyl bromide and aminoglycosides against Pseudomonas aeruginosa. | 2002 Dec |
|
Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. | 2002 Dec |
|
Perfluorooctyl bromide has limited membrane solubility and is located at the bilayer center. Locating small molecules in lipid bilayers through paramagnetic enhancements of NMR relaxation. | 2002 Dec 5 |
|
Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia. | 2002 Feb |
|
Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. | 2002 Jan |
|
Use of perflubron to enhance lung gene expression: safety and initial efficacy studies in non-human primates. | 2002 Jan |
|
Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. | 2002 Mar 15 |
|
Effect of perfluorocarbon (perfluorooctyl bromide) vapor on tidal volume measurement during partial liquid ventilation. | 2002 May |
|
New strategies in nonoperative management of meconium ileus. | 2002 May |
|
Perflubron reduces lung inflammation in respiratory syncytial virus infection by inhibiting chemokine expression and nuclear factor-kappa B activation. | 2002 May 15 |
|
Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery. | 2002 Oct |
|
Positive end-expiratory pressure modulates perfluorochemical evaporation from the lungs. | 2003 |
|
Perfluorooctyl bromide (perflubron) attenuates oxidative injury to biological and nonbiological systems. | 2003 Apr |
|
End-expiratory lung volumes and density distribution patterns during partial liquid ventilation in healthy and oleic acid-injured sheep: a computed tomography study. | 2003 Aug |
|
Mechanism of perfluoroalkyl halide toxicity: catalysis of perfluoroalkylation by reduced forms of cobalamin (vitamin B12). | 2003 Dec |
|
Transient increase in lung epithelial tight junction permeability: an additional mechanism for enhancement of lung transgene expression by perfluorochemical liquids. | 2003 Dec |
|
Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization. | 2003 Jan |
|
Effect of partial liquid ventilation on bacterial clearance during Pseudomonas aeruginosa-induced lung injury in rats. | 2003 Jul |
|
Partial liquid ventilation does not affect BALF TNF-, MIP-2, CINC-1 concentrations, or CD11b cell surface expression, but does increase macrophage proportion among BALF cells in the acute phase of rat LPS-induced lung injury. | 2003 Jun |
|
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. | 2003 Jun 16 |
|
Effect of perfluorooctyl bromide on bacterial growth. | 2003 May |
|
Perflubron emulsion improves hepatic microvascular integrity and mitochondrial redox state after hemorrhagic shock. | 2003 Nov |
|
Extended high-frequency partial liquid ventilation in lung injury: gas exchange, injury quantification, and vapor loss. | 2003 Sep |
|
Alternatives to blood in the 21st century. | 2004 |
|
Blood management in intensive care medicine: CRIT and ABC--what can we learn? | 2004 Apr |
|
[Effects of perfluorochemicals on severe hemo-diluted cardiopulmonary bypass in dogs]. | 2004 Jan |
|
Assessment of the development of choked flow during total liquid ventilation. | 2004 Jan |
|
Effects of partial liquid ventilation on lipopolysaccharide-induced inflammatory responses in rats. | 2004 Jul |
|
Surface properties and the meconium aspiration syndrome. | 2004 Mar |
|
Effect of meconium on the surface properties of perflubron. | 2004 Mar |
|
Feasibility of lung cancer hyperthermia using breathable perfluorochemical (PFC) liquids. Part I: Convective hyperthermia. | 2004 May |
|
Comparison of aerosol therapy with different perfluorocarbons in surfactant-depleted animals. | 2004 May |
|
[The impact of mechanical ventilation strategies that minimize atelectrauma in an experimental model of acute lung injury]. | 2004 May-Jun |
|
Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. | 2004 Sep |
|
Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. | 2005 Mar |
|
Brain pharmacokinetics of lignocaine before and following intravenous perfluorocarbon emulsion infusion in sheep. | 2005 May-Jun |
Sample Use Guides
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:04:29 GMT 2023
by
admin
on
Sat Dec 16 18:04:29 GMT 2023
|
Record UNII |
Q1D0Q7R4D9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08CX01
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
630718
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
631018
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
WHO-ATC |
V08CX01
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
NCI_THESAURUS |
C798
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
141100
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB05791
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
SUB09721MIG
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
DD-10
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200866
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
2102
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
Q1D0Q7R4D9
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
DTXSID5046560
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
1510801
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
C1422
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
207-028-4
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
PERFLUBRON
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
9873
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
100000082730
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
C003072
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
m8540
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
6903
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
38803
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY | |||
|
423-55-2
Created by
admin on Sat Dec 16 18:04:29 GMT 2023 , Edited by admin on Sat Dec 16 18:04:29 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |